To the full analysis
Lexicon Pharmaceuticals stock: growth
LXRXLexicon Pharmaceuticals reported $49.8M in revenue for fiscal 2025, up 60.2% on the prior year, up 15.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−2%
per year from 2006 to 2025, per share −19.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 15.7% | −9.1% | −2.0% |
| Revenue per share | −8.7% | −19.9% | −19.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $72.8M | −$54.31M | −$60.49M |
| 2007 | $50.12M | −$58.79M | −$76.22M |
| 2008 | $32.32M | −$76.86M | −$97.79M |
| 2009 | $10.7M | −$82.78M | −$89.39M |
| 2010 | $4.91M | −$101.78M | −$83.5M |
| 2011 | $1.85M | −$116.22M | −$89.14M |
| 2012 | $1.09M | −$110.21M | −$94.95M |
| 2013 | $2.22M | −$104.13M | −$92.8M |
| 2014 | $22.85M | −$100.29M | −$75.7M |
| 2015 | $130.01M | −$4.68M | $183.87M |
| 2016 | $83.34M | −$141.43M | −$175.86M |
| 2017 | $90.34M | −$129.05M | −$185.62M |
| 2018 | $63.21M | −$120.55M | −$148.7M |
| 2019 | $322.07M | $130.13M | $113.74M |
| 2020 | $24M | −$58.57M | −$143.06M |
| 2021 | $298K | −$87.76M | −$88.24M |
| 2022 | $139K | −$101.94M | −$90.18M |
| 2023 | $1.2M | −$177.12M | −$162.37M |
| 2024 | $31.08M | −$200.4M | −$179.81M |
| 2025 | $49.8M | −$50.34M | −$67.85M |
Revenue by segment
How Lexicon Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- License$45.0M90%
- Product$4.6M9%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| License | $45M | 90.4% |
| Product | $4.65M | 9.3% |
| Total revenue | $49.8M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.